Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients
Antoine N. Saliba(Mayo Clinic in Arizona), Mrinal M. Patnaik(Mayo Clinic), Rajiv K. Pruthi(Mayo Clinic), Ayalew Tefferi(Mayo Clinic), Julie A. Majerus(Mayo Clinic in Arizona), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Evandro D. Bezerra(Cleveland Clinic), Filippo Pinto e Vairo(Mayo Clinic), Eric W. Klee(Mayo Clinic), Alexandra Higgins(Mayo Clinic), Alejandro Ferrer(Mayo Clinic), Alessia Buglioni(Mayo Clinic), Naseema Gangat(Mayo Clinic in Arizona), Dong Chen(Mayo Clinic in Arizona), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 12
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k